Next Science Receives FDA Warning Letter Over Compliance Issues

The latest announcement is out from Next Science Ltd ( (AU:NXS) ).

Next Science Limited has received a Warning Letter from the US FDA following an inspection of its Jacksonville, Florida facility. The FDA identified issues related to marketing authorization, quality system regulation violations, and medical device reporting violations. Next Science has undertaken corrective actions and is committed to addressing the FDA’s concerns to ensure compliance. The company asserts that its products remain safe and effective for their intended uses.

More about Next Science Ltd

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology, owning 100% of the patent-protected intellectual property related to it.

YTD Price Performance: 21.43%

Average Trading Volume: 21,186

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $21.41M

See more data about NXS stock on TipRanks’ Stock Analysis page.